ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma
April 07, 2021announced that the European Medicine Gan & Lee Pharmaceuticals Co., Ltd. Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma. -
Drug Candidate GLR2007 Granted FDA Orphan Drug Designation
September 18, 2020Gan & Lee Pharmaceuticals announced the U.S Food and Drug Administration (FDA) has granted Orphan Drug Designation for GLR2007, for the treatment of malignant glioma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that ...
Pharma Sources Insight January 2025
